Cargando…

Oncolytic virotherapy for human malignant mesothelioma: recent advances

Cancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted activities against both tumor cells and tumor vessels, in addition to their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boisgerault, Nicolas, Achard, Carole, Delaunay, Tiphaine, Cellerin, Laurent, Tangy, Frédéric, Grégoire, Marc, Fonteneau, Jean-François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918388/ https://www.ncbi.nlm.nih.gov/pubmed/27512676 http://dx.doi.org/10.2147/OV.S66091

Ejemplares similares

Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response
por: Achard, Carole, et al.
Publicado: (2015)

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
por: Delaunay, Tiphaine, et al.
Publicado: (2020)

Natural Oncolytic Activity of Live-Attenuated Measles Virus against Human Lung and Colorectal Adenocarcinomas
por: Boisgerault, Nicolas, et al.
Publicado: (2013)

Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells
por: Achard, Carole, et al.
Publicado: (2016)

Antitumor Virotherapy by Attenuated Measles Virus (MV)
por: Guillerme, Jean-Baptiste, et al.
Publicado: (2013)

Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma
por: Blondy, Thibaut, et al.
Publicado: (2020)

Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells
por: Fonteneau, Jean-François, et al.
Publicado: (2013)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma
por: Denis, Iza, et al.
Publicado: (2014)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Oncolytic virotherapy for pediatric malignancies: future prospects
por: Waters, Alicia M, et al.
Publicado: (2016)

Oncolytic Sendai virus-based virotherapy for cancer: recent advances
por: Saga, Kotaro, et al.
Publicado: (2015)

Targeting tumor vasculature through oncolytic virotherapy: recent advances
por: Toro Bejarano, Marcela, et al.
Publicado: (2015)

Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances
por: Kwan, Amy, et al.
Publicado: (2021)

Oncolytic virotherapy: basic principles, recent advances and future directions
por: Lin, Danni, et al.
Publicado: (2023)

Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023)

Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm
por: Guan, Mingxu, et al.
Publicado: (2014)

Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
por: Ekeke, Chigozirim N., et al.
Publicado: (2021)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

Special Issue “Recent Advances in Morbillivirus Vaccine Development and Oncolytic Virotherapy”
por: Lin, Liang-Tzung
Publicado: (2020)

Oncolytic virotherapy for advanced liver tumours
por: Chang, Ju-Fang, et al.
Publicado: (2009)

Oncolytic virotherapy – in vivo veritas
por: Kemler, Iris, et al.
Publicado: (2018)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Delivery and Biosafety of Oncolytic Virotherapy
por: Li, Lizhi, et al.
Publicado: (2020)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019)

Progress of oncolytic virotherapy for neuroblastoma
por: Chen, Xiao-Tong, et al.
Publicado: (2022)

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy
por: Guan, Mingxu, et al.
Publicado: (2016)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
por: Babiker, Hani M, et al.
Publicado: (2017)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice
por: Auffinger, Brenda, et al.
Publicado: (2013)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019)

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
por: Sampath, Padma, et al.
Publicado: (2015)

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
por: Li, H, et al.
Publicado: (2010)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

The Practical Consideration of Poliovirus as an Oncolytic Virotherapy
por: Denniston, Elizabeth, et al.
Publicado: (2016)

Measles virus: Background and oncolytic virotherapy
por: Bhattacharjee, Sankhajit, et al.
Publicado: (2018)

Multidisciplinary oncolytic virotherapy for gastrointestinal cancer
por: Fujiwara, Toshiyoshi
Publicado: (2019)

Implications of MicroRNAs in Oncolytic Virotherapy
por: Bofill-De Ros, Xavier, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ietgka4tf0l59v15j9q4so2cfu